INTRODUCTION
Since the report of the U.S. Surgeon General in 1964 concluded that smoking was a cause of lung cancer, there has been growing awareness of the health risks of smoking worldwide. In 2014, the report of the U.S. Surgeon General revealed that cigarette 4 . Thereafter, several tobacco control policies were put in place, such as increasing taxes on tobacco products, ban on cigarette advertising, smoking-free zones, provincial antismoking programs, and health warning on tobacco products. Smoking prevalence among the population age 15 years and older in Thailand has fallen from 54.7% (male) and 6.1% (female) in 1976 to 37.7% and 1.7% in 2017 5, 6 . Although knowledge has expanded dramatically on the health consequences of the diseases caused by tobacco use and involuntary exposure to tobacco smoke, studies on health outcomes related to smoking in Thailand are relatively rare.
Smoking-attributable mortality (SAM), a health impact indicator for tobacco control has been well described. Many countries h av e u s e d s m o k i n g -a t t r i b u t a b l e f r a c t i o n (SAF) to estimate SAM for monitoring and evaluation of their tobacco control policies 7 . Some of these countries have extended the use of SAF to hospitalization data to estimate smoking-attributable hospitalization (SAH) [7] [8] [9] . However, SAH has been less documented, particularly in low-and middle-income countries (LMICs). To assist antismoking efforts aimed at reducing smoking prevalence in Thailand, and to help reduce the health consequences attributable to tobacco use, information on the effects of smoking on morbidity is needed. Our objective was to estimate the number of hospital admissions and costs attributable to tobacco use between 2007 and 2014 in Thailand.
METHODS

Data sources
To calculate the proportion of SAHs attributable to tobacco use, data on the prevalence of smoking, the relative risk of smokers developing a certain disease or condition, and the number of hospital admissions for such disease or condition is required 8 . Smoking prevalence data for the Thai population were obtained from the 2011 National Cigarette Smoking and Alcohol Drinking Behavior Survey, collected by the National Statistical Office 10 .
There is no comprehensive cohort study in Thailand that collects data on smoking behavior and health-related outcomes to obtain the relative risk. Therefore, a list of smoking-related conditions and their relative risks included in this study were based on the 2014 Health Consequences of Smoking-50 Years of Progress: A Report from the Surgeon General1.The report provides the widely acceptable rubric of smoking-related disease categories and the associated relative risk values that are based on the first 6 years of follow-up of the Cancer Prevention Study II during 1982-1988 (CPS-II), one of the largest U.S. cohort studies that collects smoking information 1 . Inpatient de-identified discharge data between 2007 and 2014 from three major health insurance schemes (universal coverage, social security, and civil servant schemes -accounted for nearly 99% of the Thai population) were obtained from the National Health Security Office, the Social Security Office and the Health Insurance System Research Office
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. The information presented in this study was based on any diagnosis for each hospital admission (the principal diagnosis and other up to 12 sub-diagnoses). The discharge data also provided information on total hospital charge for each admission.
Population estimates were based on 2007-2014 Thailand population statistics from Thailand's Official Statistics Registration Systems, Department of Provincial Administration and the world standard population from the WHO 12, 13 .
Calculation of smoking-attributable hospitalizations
To quantify the contribution of smoking as a risk factor for hospital admissions, the SAF for such conditions must be identified. SAF is a function of the prevalence of smoking and the relative risk 14, 15 :
where P i = prevalence of smoking in group i, with RR i = relative risk in exposed group i compared with the unexposed group, and Σ i is a summation over each i corresponding to three exposure groups (nonsmoker, former smoker, current smoker).
The SAFs were calculated across the three categories, non-smoker, current smoker, and former smoker, for each sex, then combined to estimate the overall SAF for both sexes for each disease.
To calculate the proportion of SAHs, the SAF was applied to the total number of hospital admissions for each condition. Because the relative risks used in this study were based on adults age 35 years and older, the calculation of SAHs in the present study was based on the number of hospitalizations among adults age 35 years and older.
In addition, any diagnosis was used in the analysis of the SAHs to reduce underestimation of the number of hospitalizations due to smoking when only principal diagnosis is considered 16 . Nevertheless, one admission may contain multiple smoking-related diagnoses; therefore, to prevent double counting, the diagnosis with the highest SAF was used for the calculation of the overall SAHs and each disease category. For example, if a patient was admitted to a hospital with COPD, lung cancer, and ischemic heart disease, this patient would be counted in each disease category (tobacco-related respiratory disease, tobacco-related cancer, and tobacco-related CVD), but would be counted only once in the overall SAHs.
Calculation of total hospital costs associated with smoking-attributable hospitalizations
Costs related to each hospital admission were calculated by multiplying a ratio of cost to charge (obtained from the study of standard cost lists for health technology assessment in Thailand) to the total hospital charge for each admission 17 . Then, the costs of SAHs were estimated according to the SAF of each condition.
Trend analysis of smoking-attributable hospitalizations
The direct age-standardization method was applied to calculate the age-adjusted rate of SAHs. Time trends in the annual rate of the age-adjusted rate of SAHs were examined using joinpoint regression analysis to detect changes in annual per cent change (APC) and average annual per cent change (AAPC). The trends were generated for both sexes, men and women.
AAPCs calculated by joinpoint regression analysis uses the annual per cent changes from segmented analysis to summarize and compare trends for a specific time period. The advantage of AAPCs is that it takes into account the trend transitions; whereas, the conventional annual per cent change does not and can lead to inaccurate conclusions 18 . In addition, the AAPCs during 2007-2014 for each province and geographical region were calculated and compared with those at country level. We used Joinpoint version 4.6.0.0 19 .
RESULTS
During 2007-2014, for all age groups, SAHs accounted for 4057791 hospital admissions, representing 7.3% of the total number of hospital admissions in Thailand. SAHs among adults age 35 years and older accounted for 88.1% or 3574728 admissions (71% male and 29% female; Figure 1 ).
SAHs among adults age 35 years and older were attributed to 3 major disease categories: tobacco-related cancers (8.8%), tobacco-related cardiovascular diseases (46.6%), and tobacco-related respiratory diseases (41.8%). The most common conditions of smoking-related hospitalizations were COPD (J44) with 1240128 admissions (34.7%), ischemic heart diseases (I20-I25) with 734453 admissions (20.5%), cerebrovascular diseases (I60-69) with 597100 admissions (16.7%), and other circulatory diseases (I00, I26-I51) with 589500 admissions (16.5%). Lung cancer (C33-C34) was the leading tobacco-related cancer with 249640 admissions (7.0%), followed by oropharyngeal cancer (C00-C14) with 112858 admissions (3.2%). The SAHs for each smoking-related condition are presented in Table 1 . For tobacco-related cardiovascular diseases, although their SAFs were not as high as tobaccorelated cancers and tobacco-related respiratory diseases, the number of SAHs was dominant. The trend of age-adjusted rate among men increased significantly over time (AAPC=2.5); whereas the trend among women increased insignificantly.
For tobacco-related respiratory diseases, the overall trend of age-adjusted rate increased from 2007 to 2014 (AAPC=1.4), but the trend decreased significantly over the period 2010 to 2014 (APC= -3.35). These results are shown in Table 2 and Figure 2 . The trend for bronchitis emphysema attributable to smoking was in the same direction as COPD; significantly decreased over the period 2007 to 2014 (AAPC= -4.93).
For the most common tobacco-related cancers, the trend of age-adjusted rate of lung cancer among . In contrast, the AAPCs increased significantly in 20 provinces; most of the provinces were in the southern and northeastern regions where the smoking rates were generally higher than in other parts of the country. The northeastern region had the highest number and proportion of provinces with a significant increase in AAPCs (63.2%) followed by the southern (28.6%), whereas for the central and northern regions values were far lower than the national average. The AAPC of the age-adjusted rate of the overall SAHs by province is shown in Figure  4 . The prevalence of smoking by geographical region and the AAPCs are presented in Table 4 . Hospital costs for each smoking-related condition are shown in Table 5 . Cardiovascular diseases, attributable to smoking, cost $342 million per year. In addition, average cost per SAH due to cardiovascular diseases was the 
Hospital costs associated with treating smokingattributable hospitalizations among adults age 35 years and older
DISCUSSION
Despite vigorous anti-smoking movements initiated by government and non-government agencies, smoking-attributable morbidities and their expenditures show no detectable decline.
In fact, studies in many countries show that disease burden attributable to smoking generally increases despite the reduction in smoking prevalence 1, 20, 21 . Passive smoking could be one explanation. In the present study it was found that the male-to-female overall SAH ratio was inconsistent with the current male-to-female smoking prevalence ratio (2.4 vs 22.2). This finding indicates that the high morbidity among women, even though smoking prevalence is relatively low, may be due to passive smoking, however, this issue needs further investigation. Another explanation could be the latency between smoking exposure and disease onset [22] [23] [24] [25] . In addition, a risk reduction of smoking-related diseases was observed after several years of smoking cessation. For instance, a study indicated that the excess risk of developing COPD, lung cancer, and ischemic heart disease become half following quitting smoking with varying duration: 13.3, 9.9, and 4.4 years, respectively 24, 26 . Furthermore, a well-established model indicates that for the substantial health hazards of tobacco use in developed countries there is a three to four decade lag between the peak in the prevalence of smoking and the subsequent peak in smoking-attributable mortality 27, 28 . However, the lag time between the smoking prevalence and the smoking-related mortality and morbidity in low-and middle-income countries has not been established.
The timeframe of this study is too short to determine at what stage Thailand's smoking epidemic curve is currently at; nevertheless, with continuous monitoring, this will become clearer over several years. For example, the significant reduction in the average annual per cent change of COPD found in this study in the last four years could be a result of the huge decline in smoking prevalence in Thailand more than decades ago. Average annual per cent changes during the study period might also be a result of significant increased access to healthcare subsequent to the commencement of the universal health coverage in 2002 29 . The increasing trend in age-specific rate of SAHs emphasizes the need for more intensive anti-smoking interventions over an extended time span. It also indicates a need for strengthening primary care to minimize the needs for hospitalization among patients with smokingrelated diseases 30 . The present study also demonstrates that Thailand spends about $572 million annually on treating patients admitted to hospitals because of smoking and the costs have tended to increase over time (16.3% of the total hospital cost in 2007 to 18.3% in 2014). Furthermore, there are other costs attributable to smoking, such as direct medical costs in outpatient units and other indirect costs. A study in 2009 estimated overall economic loss in Thailand due to smoking was $2255 million annually; whereas the excise department reported that the annual tobacco tax collection was only $1323 million 31, 32 . This seemingly net economic loss from cigarette smoking helps to justify population-based interventions targeting reduction in tobacco use. In effect, recent evidence from a systematic review substantiates the cost-effectiveness of the interventions in low-and middle-income countries with potential to generate economic gains that can be reinvested to improve health and/or other sectors 33 .
Globally socioeconomic inequalities in all forms of tobacco use are well established 34 and our findings on the distributions of SAHs among the genders (Table 2 ) and geographical regions (Table 4) conform to this inequality patterns. The average annual per cent change of SAHs in the northeast and the south seems to be higher than in other regions. Concurrently, smoking prevalence rates of the northeast and the south are generally higher than in other regions. The geographic variation of SAHs in Thailand can be caused by several factors. Different patterns of cigarette smoking could be one leading cause, as more than 60% of people in the northeastern region, a higher rate than in other regions, prefer hand rolled cigarettes that are much cheaper than regular cigarettes due to lower tax rates 10 . Other factors are lower socioeconomic characteristics such as income and education compared to others. The northeastern region also has the lowest physicianto-population ratio and poor access to smoking cessation services.
There are limitations of the study. This study is based on hospitalization data only and so could underestimate effects of tobacco-related morbidity, especially those who did not receive care in a hospital or were treated in outpatient departments. Also, misdiagnosis or wrongly assigned a diagnosis-related group (DRG) coding is possible 35 . Furthermore, variations in access to care by region may exist. Moreover, accuracy and completeness of the fill-in data may be different by region. Lastly, this study did not include the effects of secondhand smoke.
The present study has strengths by including three national data sources that cover almost all hospitalizations of the Thai population and by showing a time trend. In addition, the advantage of using hospital discharge data is that they are a readily available to the public, periodically updated, and are a nationally representative data set 36 . Hence long-term monitoring of health impacts of tobacco use is enabled using hospital discharge data. Finally, our study complements the conventional surveys on smoking prevalence.
CONCLUSIONS
Smoking remains a significant health and economic burden in Thailand. Although, Thailand has made good progress on implementing many smoking control interventions recommended by the FCTC, the current sluggish decline in smoking prevalence indicates that further improvements are needed to increase effectiveness of the programs and reduce diseases caused by smoking. Findings from this study pose a compelling reason for Thailand to advance tobacco control efforts to reduce the financial and social burden of disease caused by smoking. Emphasis on more effective implementation of population-based interventions could prevent youth smokers and motivate attempts to quit among current smokers. In addition, strengthening primary care could prevent unnecessary hospitalization of patients with smoking-related diseases and reduce healthcare costs.
